EpilepsyGTx
Canterbury
About EpilepsyGTx
EpilepsyGTx is a late-stage biotech company exploring cutting-edge gene therapies to improve the management of focal refractory epilepsy (FRE).
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $43.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Dec 2025)
- Website: epilepsygtx.com
- Phone: +44 7717 801 246
Industries & Categories
Biotechnology, Clinical Trials, Medical
Social Profiles
Canonical: https://fsome.com/organization/epilepsygtx-85241 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.